Generic Name: dasabuvir, ombitasvir, paritaprevir, and ritonavir (da SAB ue vir, om BIT as vir, PAR i TAP re vir, and rye TON a vir)
Brand Names: Viekira Pak, Viekira XR
What is Viekira?
Viekira is an antiviral medicine containing a combination of dasabuvir, ombitasvir, paritaprevir, and ritonavir. These four drugs are antiviral medicines that prevent hepatitis C virus (HCV) from multiplying in your body.
Viekira is a combination medicine used to treat genotype 1 chronic hepatitis C in adults, including people with a certain type of cirrhosis.
Viekira is sometimes given together with another drug called ribavirin.
Do not use Viekira together with ribavirin if you are pregnant, or if you are a man and your sexual partner is pregnant.
Before you start taking Viekira, you must stop using certain birth control pills or hormone replacement medicines. Ask your doctor about using non-hormonal birth control to prevent pregnancy.
If you have ever had hepatitis B, Viekira can cause this condition to come back or get worse. You will need frequent blood tests to check your liver function.
Before taking Viekira
You should not use Viekira if you are allergic to dasabuvir, ombitasvir, paritaprevir, or ritonavir, or if:
you have moderate to severe liver disease; or
you have ever had a severe skin rash after taking ritonavir (Norvir).
If you take Viekira with ribavirin: There may be other reasons you should not take this combination treatment. Tell your doctor about all your medical conditions.
Some medicines can interact with Viekira and should not be used at the same time. Your doctor may need to change your treatment plan if you use:
efavirenz (Atripla, Sustiva);
sildenafil (Revatio), when taken for pulmonary artery hypertension (PAH);
St. John's wort;
oral midazolam (Versed), or triazolam;
birth control pills or patches - Lo Loestrin FE, Norinyl, Ortho Tri-Cyclen Lo, Ortho Evra, and others;
hormone replacement therapy such as Fem HRT;
a vaginal ring such as NuvaRing;
cholesterol-lowering medicine - gemfibrozil, lovastatin, simvastatin (Zocor, Vytorin, Simcor);
ergot medicine - dihydroergotamine, ergotamine, methylergonovine; or
seizure medicine - carbamazepine, phenytoin, phenobarbital.
Before you start taking Viekira, you must stop using medicine that contains ethinyl estradiol. This includes certain birth control pills or hormone replacement medicines. Ask your doctor about using non-hormonal birth control (condom, diaphragm with spermicide) to prevent pregnancy while taking Viekira and for 2 weeks after your treatment ends.
To make sure Viekira is safe for you, tell your doctor if you have:
a history of hepatitis B;
liver problems other than hepatitis;
HIV (human immunodeficiency virus); or
if you have received a liver transplant.
Viekira is not expected to harm an unborn baby. Tell your doctor if you are pregnant. Your name may be listed on a pregnancy registry. This is to track the outcome of the pregnancy and to evaluate any effects of Viekira on the baby.
If you also take ribavirin, you may need to have a negative pregnancy test before your treatment starts. Ribavirin is known to cause birth defects or death in an unborn baby.
While you are taking Viekira with ribavirin: Use birth control to prevent pregnancy whether you are a man or a woman. Ribavirin use by either parent may cause birth defects. Tell your doctor right away if a pregnancy occurs while either the mother or the father is taking ribavirin.
It is not known whether this medicine passes into breast milk or if it could harm a nursing baby. Tell your doctor if you are breast-feeding a baby.
How should I take Viekira?
Viekira is usually taken for 12 to 24 weeks. Follow all directions on your prescription label. Do not take this medicine in larger or smaller amounts or for longer than recommended.
Take this medicine with food.
Viekira XR is an extended-release form of this combination medicine to be taken once daily. Viekira XR is supplied as 3 pale yellow tablets that are taken all at once with a daily meal.
The Viekira Pak contains two different types of tablets. The pink tablet contains only ombitasvir, paritaprevir, and ritonavir. The beige tablet contains only dasabuvir.
Take 2 pink tablets plus 1 beige tablet at the same time every morning. Take 1 beige tablet at the same time every evening.
The monthly Viekira XR or Viekira Pak carton contains enough tablets for you to take this medicine for 4 weeks (28 days in a row).
You will need frequent blood tests to check your liver function.
Hepatitis C is often treated with a combination of drugs. Use all medications as directed by your doctor. Read all patient information, medication guides, and instruction sheets provided to you. Do not change your doses or medication schedule without your doctor's advice. Every person with chronic hepatitis C should remain under the care of a doctor.
You should not stop using this medicine suddenly. Stopping suddenly could make your condition harder to treat with hepatitis C antiviral medicine.
If you have ever had hepatitis B, Viekira can cause this condition to come back or get worse. You will need liver function tests during treatment and for several months after you stop using this medicine.
Store at room temperature away from moisture and heat. Do not remove the tablets from a daily dose package until you are ready to take the medicine.
Viekira dosing information
Usual Adult Dose for Chronic Hepatitis C:
Dasabuvir: 250 mg orally twice a day (morning and evening)
Ombitasvir/paritaprevir/ritonavir fixed-dose combination tablet: 2 tablets orally once a day (in the morning)
Recommended Regimen and Duration of Therapy:
-Genotype 1a, without cirrhosis: Dasabuvir, ombitasvir/paritaprevir/ritonavir, and ribavirin for 12 weeks
-Genotype 1a, with cirrhosis: Dasabuvir, ombitasvir/paritaprevir/ritonavir, and ribavirin for 24 weeks (12 weeks may be considered for some patients based on prior treatment history)
-Genotype 1b, without cirrhosis: Dasabuvir and ombitasvir/paritaprevir/ritonavir for 12 weeks
-Genotype 1b, with cirrhosis: Dasabuvir, ombitasvir/paritaprevir/ritonavir, and ribavirin for 12 weeks
Liver transplant recipients with normal liver function and mild fibrosis (Metavir fibrosis score 2 or lower): Dasabuvir, ombitasvir/paritaprevir/ritonavir, and ribavirin for 24 weeks, regardless of HCV genotype 1 subtype
-Before starting this product, patients should be assessed for laboratory and clinical evidence of hepatic decompensation.
-Recommended for therapy-naive or interferon-experienced patients, including those with HCV/HIV-1 coinfection
-The dosing recommendations for genotype 1a should be followed for patients with unknown genotype 1 subtype or with mixed genotype 1 infection.
-The manufacturer product information should be consulted for ribavirin dosing recommendations (if applicable), regarding dosing of concomitant HIV-1 antiviral drugs in HCV/HIV-1 coinfected patients, and regarding use with calcineurin inhibitors in liver transplant recipients.
Use: With or without ribavirin, for the treatment of patients with genotype 1 chronic HCV infection, including those with compensated cirrhosis
See also: Dosage Information (in more detail)
What happens if I miss a dose?
If you miss a dose of the pink tablets, take the missed dose with a meal as soon as you remember. If you are more than 12 hours late, skip the missed dose and take your next dose at the usual time with a meal.
If you forget to take the beige tablet, take it with a meal as soon as you remember. If you are more than 6 hours late in taking the beige tablet, skip the missed dose and take your next dose at the usual time with a meal.
Do not take extra medicine to make up a missed dose.
What happens if I overdose?
Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.
What should I avoid while taking Viekira?
Taking Viekira will not prevent you from passing hepatitis C to other people. Do not have unprotected sex or share razors or toothbrushes. Talk with your doctor about safe ways to prevent HCV transmission during sex. Sharing drug or medicine needles is never safe, even for a healthy person.
Viekira side effects
Get emergency medical help if you have signs of an allergic reaction to Viekira: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have:
liver problems - nausea, upper stomach pain, itching, tired feeling, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).
Common Viekira side effects may include:
itching, skin rash or redness;
sleep problems (insomnia); or
feeling weak or tired.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
See also: Side effects (in more detail)
What other drugs will affect Viekira?
When you start or stop taking Viekira, your doctor may need to adjust the doses of any other medicines you take on a regular basis.
Many drugs can interact with dasabuvir, ombitasvir, paritaprevir or ritonavir. Tell your doctor about all your current medicines and any you start or stop using, especially:
amlodipine (Norvasc, Amturnide, Azor, Caduet, Exforge, Lotrel, Tekamlo, Tribenzor, Twynsta);
heart rhythm medicine;
medicine to treat HIV or AIDS;
antifungal medicine - ketoconazole, voriconazole;
asthma or allergy medicine - Flonase, Veramyst, Flovent, Advair, Arnuity Ellipta, Serevent Diskus, and others;
cholesterol medication - rosuvastatin (Crestor), pravastatin (Pravachol); or
medicine to prevent organ transplant rejection - cyclosporine, tacrolimus.
Many drugs can interact with dasabuvir, ombitasvir, paritaprevir, and ritonavir, and some drugs should not be used together. This includes prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide. Tell your doctor about all medicines you use, and those you start or stop using during your treatment with Viekira.
More about dasabuvir/ombitasvir/paritaprevir/ritonavir
- Dasabuvir, ombitasvir, paritaprevir, and ritonavir (Advanced Reading)
- Ombitasvir, paritaprevir, ritonavir and dasabuvir (Advanced Reading)
- Ombitasvir, Paritaprevir, and Ritonavir with Dasabuvir Sodium (AHFS Monograph)
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir (Wolters Kluwer)
Related treatment guides
Where can I get more information?
- Your pharmacist can provide more information about Viekira.
- Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use Viekira only for the indication prescribed.
- Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 1996-2017 Cerner Multum, Inc. Version: 1.08.
Date modified: November 30, 2016
Last reviewed: May 25, 2016